The FDA granted accelerated approval to tisagenlecleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Tisagenlecleucel (Kymriah, Novartis) — developed by Novartis in collaboration with University of Pennsylvania — is an autologous, gene-edited, CD19-directed chimeric antigen receptor T-cell therapy.
The agent is also approved in the U.S. for patients aged 25 years or younger with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, as well as adults with diffuse large B-cell lymphoma, high-grade